secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041292
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q2 commercial revenue up 42% to $11.7M; raises FY2023 guidance to $51-53M; two FDA approvals
--------------------------------------------------------------------------------

- Commercial revenue $11.7M (+42% YoY); net loss $0.41/share vs $0.25 loss in prior year.
- FDA approved RECELL for full-thickness skin defects (June 7) and vitiligo repigmentation (June 16).
- FY2023 revenue guidance raised to $51-53M from prior $49-51M; Q3 guidance $13-14M.
- RECELL GO PMA supplement submitted; FDA decision expected by December 27, 2023.
- Cash $68.8M, no debt; gross margin guided 83-85% for FY2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/0000950170-23-041292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017023041292/rcel-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer